Similarly, after treatment with anti-VEGFR2 or anti-angiogenin 2 and VEGF-A bispecific antibodies, the disruption of VEGFR2 signaling enhanced the effector function of T cells in ovarian cancer patients and mouse tumors [35–38] which was consistent with our results. The gene discussed is VEGFA; the disease is ovarian carcinoma.